Alogliptin (NESINA), a dipeptidyl peptidase IV (DPP-4) inhibitor, was approved by the FDA on January 25, 2013 to improve blood sugar control in adults with type 2 diabetes. This drug had been ...

Use of sodium glucose cotransporter 2 (SGLT-2) inhibitor drugs to treat type 2 diabetes may also help to lower the risk of ...

New research presented at the ACG Annual Meeting suggests that GLP-1RAs lower the risk of pancreatic cancer in patients with ...

In drug-naïve subjects with type 2 diabetes ... The studies presented thus far therefore suggest that DPP-4 inhibition is an efficient treatment of type 2 diabetes, both as monotherapy and ...

"The findings from these target trial emulations indicate that SGLT-2 inhibitors could be a valuable addition to existing ...

New study reports protective effect among people with type 2 diabetes Kidney stones and the systemic conditions associated with them have a major impact on health and the economy in the US and ...

There is also a strong rationale provided to avoid use of sliding-scale insulin and to consider the use of oral agents and ...

Rate this content's potential impact on patient outcomes Submit Rating Thank you! Please share some more information on the ...

For patients with nephrolithiasis, sodium-glucose cotransporter-2 (SGLT-2) inhibitor use is associated with a reducti ...

DPP directions are expected in ... of the Misuse of Drugs Act 1977 as amended and contrary to Section 71 (1) (a) (4) of the Criminal Justice Act 2006 as amended by Section 4 (b) of the Criminal ...